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Summary
Background.— High-sensitivity cardiac troponin assays have improved the detection of acuteHigh-sensitivity
assay;
Copeptin;
Acute coronary
syndrome;
Unstable angina
coronary syndrome.
Aim.— To examine the possible incremental value of copeptin in the detection of acute coronary
syndrome.
Methods.— We designed a prospective cohort study to compare the performance of high-
sensitivity cardiac troponin T (hs-cTnT) measured at admission in combination with copeptin,
and the performance of hs-cTnT alone, measured at admission, 3 hours and 6 hours, in patients
Abbreviations: ACS, acute coronary syndrome; AMI, acute myocardial infarction; cTn, cardiac troponin; cTnI, cardiac troponin I; cTnT,
ardiac troponin T; CV, coefﬁcient of variation; ECG, electrocardiogram; hs-cTn, high-sensitivity cardiac troponin; hs-cTnT, high-sensitivity
ardiac troponin T; ROC, receiver operating characteristic.
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with suspected acute coronary syndrome of < 6 hours’ duration after onset of symptoms (exclu-
sion of patients with ST-segment elevation myocardial infarction).
Results.— Fifty-eight consecutive patients fulﬁlled our criteria and were included. After
detailed investigations, the ﬁnal adjudicated diagnosis was acute coronary syndrome in 30
patients (including acute myocardial infarction in 13 and unstable angina in 17) and non-
acute coronary syndrome in 28 patients. Measured on admission, hs-cTnT concentration
was > 14 ng/mL (99th percentile) in 22 patients with acute coronary syndrome; repetition of the
measurement at 3 hours and 6 hours identiﬁed three and four additional patients, respectively.
The combination of copeptin with hs-cTnT determined on admission identiﬁed 26 patients with
acute coronary syndrome, with a negative predicted value of 82.6%. The area under the receiver
operating characteristic curve was 0.90 for hs-cTnT measured on admission, and 0.94 if repeated
at 3 hours and 6 hours or combined with copeptin measurement at admission (non-signiﬁcant
difference).
Conclusions.— This prospective study demonstrated that a dual marker strategy that combines
hs-cTnT with copeptin increased slightly the detection of acute coronary syndrome at admission.
© 2010 Elsevier Masson SAS. All rights reserved.
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Résumé
Rationnel.— Les troponines hyper-sensibles (Tn-hs) améliorent la détection des syndromes
coronariens aigus (SCA).
Objectif.— Étudier la possible amélioration de la détection des SCA offerte par l’association
de copeptine avec la TnT-hs.
Méthodes.— Cohorte prospective qui a comparé les performances de TnT-hs mesurée à
l’admission et associée à la copetine, à la mesure de TnT-hs seule, à l’admission, trois heures
et six heures, chez les patients suspects de SCA évoluant depuis moins de six heures (exclusion
des patients avec infarctus du myocarde avec sus-décalage du segment ST).
Résultats.— Cinquante-huit patients consécutifs ont été inclus. Le diagnostic ﬁnal était SCA
chez 30 patients (13 patients avec IDM et 17 avec angor instable), et non-SCA pour 28 patients.
Mesurée à l’admission, la TnT-hs était supérieure à 14 ng/mL (99e percentile) chez 22 patients
avec SCA. La répétition des dosages à trois heures a permis de détecter trois patients supplé-
mentaires, et à six heures quatre patients supplémentaires. La mesure conjointe de copeptine
et de TnT-hs a détecté 26 patients avec SCA, et sa valeur prédictive négative pour le diagnostic
de SCA est de 82,6 %. L’aire sous la courbe de la courbe ROC est de 0,9 pour la TnT-hs mesurée
à l’admission, 0,94 pour la mesure répétée à trois heures, six heures ou la mesure combinée de
copeptine et de TnT-hs à l’admission (p non signiﬁcatif).
Conclusion.— Cette cohorte prospective montre que l’utilisation combinée de copeptine et de
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Background
The management of patients with chest pain-related symp-
toms remains an important clinical challenge [1]. The
adequate ruling out of ACS in patients with chest pain is
crucial, as the erroneous discharge of a patient with ACS
is associated with a high risk of cardiac events [2,3]. Over
the past decades, cTns have emerged as key biomarkers
for patients with acute chest pain, and have undoubtedly
improved the rate of detection of occult ACS [4—7]. hs-cTn
assays have been developed recently, enabling measure-
ments of concentrations that are ∼10-fold lower than those
previously measurable. Recent studies have conﬁrmed the
increased accuracy of these high-sensitivity assays com-
pared with conventional assays in the early detection of
AMI [8—10]. However, concerns have been raised about a
possible speciﬁcity deﬁcit with these new assays [11—13].
T
u
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modestement la détection des SCA.
s droits réservés.
n addition, a second measurement of hs-cTn may be war-
anted in order to increase the accuracy of the assay [8,14].
dentiﬁcation of the perfect biomarker remains an unmet
eed, and many researchers have advocated multimarker
esting [15].
The arginine-vasopressin system plays a crucial role in
he regulation of the individual endogenous stress response
16]. Previous studies have demonstrated that copeptin (the
-terminal part of the vasopressin prohormone) is increased
n AMI [17—19]. Moreover, copeptin measurement adds valu-
ble information to conventional assays of cTn in the early
etection of AMI, according to two recent studies [17,19].
he possible merit of copeptin in addition to hs-cTn is
nknown. This study examined the diagnostic accuracy of
erial measurements of hs-cTn (at 0, 3 and 6 hours after
dmission) and of the combination of copeptin with hs-cTn
easured on admission, in the detection of ACS.
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itudy population and methods
etween June and November 2009, we enrolled consecutive
atients who were admitted to the Department of Cardiol-
gy of Cochin Hospital (Paris, France) for suspected recent
CS, deﬁned as chest pain of ≤ 6 hours’ duration since onset,
uggestive of myocardial ischaemia, and lasting > 5minutes
t rest or upon minimal exertion. Patients presenting after
cardiac arrest or with ST-segment elevation myocardial
nfarction were excluded from the study.
This study was approved by the ethics committee of
ochin Hospital and all patients granted their written
nformed consent to participate.
linical assessment and investigations
pon admission to the hospital, all patients underwent a
etailed clinical evaluation, including medical history, 18-
ead ECG, continuous bedside ECG monitoring, screening
lood tests and chest X-ray. Decisions to obtain an echocar-
iogram or coronary angiograms were left to the discretion
f the primary physicians. Analysis of cTn was done using a
onventional cTnI assay for routine assessment of patients
nd an hs-cTnT assay for research purposes.
onventional cardiac troponin I assay
easurement of cTnI was done using an Xpand® HM analyser
Siemens Healthcare Diagnostics Inc., Newark, NJ, USA). The
9th percentile is achieved at 0.07g/L with a CV between
5 and 22%; a CV≤ 10% between measurements is achieved
t 0.14g/L.
igh-sensitivity cardiac troponin T assay
s-cTnT (Roche Diagnostic, Meylan, France) was measured
n heparinized samples collected on admission, and at 3 and
hours. The assay was performed on an Elecsys® 2010 anal-
ser using an electrochemiluminescence immunoassay. The
nalytical performances of this assay have been previously
eported; the 99th percentile with a CV < 10% is achieved at
4 ng/L [11]. In our laboratory, the CV was found to be < 4%
3.6% at 27.5 ng/L and 2.8% at 2.36 ng/L).
opeptin measurements
opeptin was measured in heparinized samples collected on
dmission. The assay was performed on a Kryptor® anal-
ser using the commercial sandwich immunoluminometric
ssay (Brahms Copeptin Kryptor, Brahms Aktiengesellschaft,
ennigsdorf, Germany). The assay principle lies in Time-
esolved Ampliﬁed Cryptate Emission (TRACE) technology.
he lower detection limit is 4.8 pmol/L and the functional
ssay sensitivity (< 20% interassay CV) is < 12 pmol/L. The
imit of quantiﬁcation is 14.1 pmol/L (data from manufac-
urer). In our laboratory, the CV was found to be < 5% (4.4%
t 28.86 pmol/L and 4.6% at 95.84 pmol/L).djudication of the ﬁnal diagnosis
wo independent cardiologists adjudicated the ﬁnal diagno-
is based on all medical charts; disagreements were settled
C
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y consensus. ACS was deﬁned as AMI or unstable angina.
MI was diagnosed when there was evidence of myocar-
ial necrosis in association with clinical signs of myocardial
schaemia. Necrosis was diagnosed on the basis of a rising or
alling pattern of cTnI concentration (conventional assay),
ith at least one value above the 99th percentile, at a level
f imprecision of < 10% [7,20]. Unstable angina was diag-
osed in the presence of: clinical manifestations suggestive
f myocardial ischaemia, without evidence for myocardial
ecrosis; an ECG indicative of ongoing ischaemia or a > 70%
tenosis of an epicardial coronary artery on coronary angiog-
aphy (> 50% of the left main trunk); and the absence of an
lternative diagnosis.
A non-ACS was deﬁned in the presence of a cardiac but
on-coronary diagnosis, non-cardiac origin or when the diag-
osis remained unknown despite careful investigations.
tatistical analysis
he data are expressed as means± standard deviations for
ontinuous variables, and numbers and percentages for
ategorical variables. As cTn and copeptin measurements
ay not have a normal distribution, they are reported as
edians [25th—75th percentile]. Continuous variables were
ompared using Student’s t test for normally distributed
ariables and the non-parametric Mann-Whitney test for
on-normally distributed variables. Categorical variables
ere compared using the Chi2 test or Fisher’s exact test,
s appropriate. ROC curves were generated to assess sensi-
ivity and speciﬁcity throughout the concentration ranges of
s-cTnT and copeptin, and to compare the ability of hs-cTnT
lone and in combination with copeptin to diagnose ACS,
ompared as suggested by DeLong et al. [21]. A p value < 0.05
as considered signiﬁcant. The STATA statistical software,
ersion 10.1 (StataCorp LP, College Station, TX, USA) was
sed for all analyses.
esults
aseline characteristics and diagnosis of acute
oronary syndrome
ifty-eight patients fulﬁlled our inclusion criteria during the
tudy period; their characteristics are reported in Table 1.
he ﬁnal adjudicated diagnosis was ACS in 30 patients,
ncluding 13 patients with AMI (non-ST-segment elevation
yocardial infarction) and 17 patients with unstable angina;
CS was excluded in 28 patients. The diagnosis was based on
omplete medical charts that were available for all patients,
ncluding ECG record during chest pain in 33% of patients,
chocardiography recorded on admission in 69% of patients,
nd coronary angiogram available data in 83% of patients.
atients with ACS as their ﬁnal adjudicated diagnosis were
lder than those without ACS and had more frequent ST-
egment changes on ECG; other characteristics were similar
n both groups (Table 1).opeptin and high-sensitivity cardiac troponin
measurements
s-cTnT measured on admission was increased in patients
ith ACS as their ﬁnal adjudicated diagnosis compared
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Table 1 Baseline characteristics and presentation in the overall population and according to ﬁnal diagnosis.
All patients(n = 58) Patients with ACS (n = 30) Patients without ACS (n = 28) P valuea
Age (years) 57.9± 13.5 61.8± 13.6 53.7± 12.3 0.022
Men/women (n/n) 37/21 22/8 15/13 0.118
Coronary risk factors
Hypertension 24 (41.4) 14 (46.7) 10 (35.7) 0.397
Hypercholesterolaemia 22 (37.9) 14 (46.7) 8 (26.7) 0.156
Diabetes 13 (22.4) 8 (26.7) 5 (17.9) 0.421
Obesity 19 (32.8) 11 (36.7) 8 (28.6) 0.512
Family history 20 (34.5) 7 (23.3) 13 (46.4) 0.064
Current smoking 19 (32.8) 8 (26.7) 6 (21.4) 0.591
Past medical history
Myocardial infarction 12 (20.7) 5 (16.7) 7 (25.0) 0.434
Coronary revascularization 11 (19.0) 6 (20.0) 5 (17.9) 0.574
Drug regimen
Aspirin 20 (34.5) 9 (30.0) 11 (39.4) 0.47
Clopidogrel 9 (15.5) 4 (13.3) 5 (17.9) 0.726
Beta-adrenergic blocker 18 (31.0) 8 (26.7) 10 (35.7) 0.457
ACE inhibitor or ARB 20 (34.5) 11 (36.7) 9 (32.1) 0.717
Statin 24 (41.4) 12 (40.0) 12 (42.9) 0.825
Duration of chest pain (hours) 3.2± 1.4 7.5± 8.6 7.6± 11.7 0.953
Electrocardiogram
Q wave 7 (12.1) 6 (14.0) 4 (9.1) 0.477
ST-segment depression 12 (20.7) 10 (23.3) 3 (6.8) 0.039
T-wave inversion 16 (28.1) 20 (47.6) 12 (27.3) 0.051
Echocardiography
Recorded on admission 40 (69.0) 32 (74.4) 30 (68.2) 0.520
Abnormal wall motion 11 (19.0) 13 (30.2) 6 (13.6) 0.061
Screening blood tests
Creatinine (mol/L) 94± 37 97± 28 91± 44 0.484
GFR (mL/min/1.73 m2) 77± 20 73± 20 81± 20 0.111
cTnI > 0.07g/L on admissionb 14 (46.7) 14 (46.7) 0 (0.0) < 0.001
cTnI > 0.07g/L at 6 hoursb 18 (60.0) 18 (60.0) 0 (0.0) < 0.001
ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blocker; GFR: glomerular ﬁltration rate; cTnI: cardiac troponin I.
Values are means± standard deviations or numbers (%) of observations in the corresponding group, unless otherwise indicated.
a Between patients with ACS and patients without ACS.
b 0.07g/L is the 99th percentile of the method (cTnI), with a coefﬁcient of variation > 10%.
d
T
a
ﬁ
A
v
d
u
vwith in patients without ACS (43 [14—108] vs 4 [2—8] ng/L,
respectively; p < 0.001). Hs-cTnT measured on admission
accurately detected 22 patients with ACS; hs-cTnT measure-
ment at 3 and 6 hours resulted in the detection of three and
four additional patients with ACS, respectively. Copeptin
concentration measured on admission was not statistically
different in patients with and without ACS (10.7 [7.2—22.2]
vs 12.2 [6.0—27.8] pmol/L, respectively; p = 0.687). Indeed,
copeptin concentration was 10.3 [6.5—14.9] pmol/L in
patients with non-cardiac (or unknown) origin of chest
pain and 38.4 [7.7—56.7] pmol/L in patients with cardiac
but non-coronary cause of chest pain (cardiac syncope in
one and acute heart failure in two patients). In addition,
copeptin concentration was below the 14 pmol/L cutoff
value in six patients with AMI as their ﬁnal adjudicated
0
0
0
ciagnosis; their main characteristics are summarized in
able 2.
The combination of copeptin and hs-cTnT measured on
dmission accurately identiﬁed 26 patients with ACS as their
nal adjudicated diagnosis, including 13/13 patients with
MI. Table 3 shows the sensitivity, speciﬁcity and predictive
alues of hs-cTnT, copeptin and their combination in the
etection of ACS.
The accuracy of ACS diagnosis, ascertained by area
nder the ROC curve, was 0.90 [95% conﬁdence inter-
al 0.81—0.99] for hs-cTnT measured on admission,
.94 [0.88—1.00] for hs-cTnT measured at 3 hours,
.94 [0.88—1.00] for hs-cTnT measured at 6 hours, and
.94 [0.88—1.00] for the combination of hs-cTnT and
opeptin measured on admission (p = not signiﬁcant vs
8 C. Meune et al.
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the performance of the combination of copeptin with high-
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mensitivity cardiac troponin T (hs-cTnT) measured at admission, and
s-cTnT alone measured at admission, 3 hours and 6 hours, in the
iagnosis of acute coronary syndrome.
s-cTnT measured on admission, for each comparison)
Fig. 1).
iscussion
his prospective study examined the value of a dual marker
trategy that combines a high-sensitivity assay of cTn (a sen-
itive maker of cardiac necrosis) and copeptin (a marker of
ndogenous stress) in patients with suspected ACS. Results
ere compared with a single strategy using hs-cTnT mea-
ured at admission, 3 hours and 6 hours. We observed that
he combination of these markers ruled out ACS at pre-
entation with a negative predictive value of 82.6%. In
omparison, the negative predictive values of hs-cTnT mea-
ured on admission and after 3 hours were 76.5 and 83.9%,
espectively.
The accurate identiﬁcation of ACS is challenging [3,4].
umerous studies have demonstrated the superiority of cTn
ver various other markers in the detection of AMI and over-
ll ACS [5,6,22]. Despite the recent development of sensitive
ssays of cTn, enabling measurement of concentrations that
re 10-fold lower than those previously measurable, dupli-
ate measurements are advocated in order to increase the
ccuracy of the method [8,14]. Indeed, the retrospective
nalysis of the PROTECT-TIMI-30 trial suggested increased
etection of unstable angina when cTn measurement is
epeated after 2 and 8 hours [14], whereas Giannitsis et al.
ecommended hs-cTn measurement on admission and after
hours [8]. Our study is consistent with these studies, as the
easurement of hs-cTnT 3 hours after admission resulted in
he detection of 13% more patients. Such a diagnostic uncer-
ainty after the ﬁrst cTn measurement may have clinical and
conomic implications, and previous studies have estimated
he additional cost to exceed one billion dollars annually in
he USA [23,24].
As no marker has supplanted cTn, despite extensive
esearch [22,25—27], many researchers have advocated
ultimarker testing [15]. The combination of cTn (a marker
f cardiac necrosis) with markers of different origins and
odes of release should theoretically add diagnostic infor-
ation. Copeptin is the c-terminal part of the vasopressin
High-sensitivity troponin and copeptin in ACS 9
Table 3 Sensitivity, speciﬁcity and predictive value of high-sensitivity cardiac troponin T, copeptin and their combination
in the ﬁnal diagnosis of acute coronary syndrome.
Sensitivity Speciﬁcity Predictive values
Positive Negative
Hs-cTnT > 14 ng/L on admissiona 73.3 92.9 91.7 76.5
Hs-cTnT > 14 ng/L at 3 hoursa 83.3 92.9 92.6 83.9
Hs-cTnT > 14 ng/L at 6 hoursa 86.7 92.9 92.9 86.7
Copeptin > 14 pmol/L on admissionb 44.8 70.4 61.9 54.3
Copeptin > 14 pmol/La or hs-cTnT > 14 ng/Lb on admission 86.7 70.4 76.5 82.6
Hs-cTnT: high-sensitivity cardiac troponin T. Values are % of observations in the corresponding group.
a 14 ng/L is the 99th percentile of the assay, with a coefﬁcient of variation < 10%.
prev
o
t
w
c
3
o
a
f
L
O
p
c
b
s
p
t
m
p
e
i
n
d
C
I
d
(
t
l
s
ob 14 pmol/L cutoff value is based on data from manufacturer and
prohormone, and is equimolar to vasopressin. The patho-
physiology of copeptin secretion is therefore independent of
cardiac cell necrosis and involves endocrine stress response.
The accuracy of copeptin in the detection of AMI has been
recently highlighted [17—19]. In these studies, the accuracy
of copeptin alone was limited, but it added incremen-
tal value to the conventional cTn assay, and was even
more valuable early after the onset of symptoms [17,19]
In our study, we observed that six patients with AMI as
their ﬁnal adjudicated diagnosis had low concentrations of
copeptin < 14 pmol/L. The measuring method we used may
account in part for the observed low sensitivity. Indeed, our
method for measuring copeptin is not as analytically sensi-
tive as that used in other studies [17,19]. With the Lumitest®
method used by Reichlin et al. (which has been shown to
have a lower detection limit [0.4 pmol/L] and a better pre-
cision for low concentrations [19]), the time of analysis is
more important (about 120minutes vs 20minutes for our
method). Manufacturers should develop a more sensitive
method of copeptin measurement, adapted to emergency
practice, in order to secure copeptin’s place in the list
of AMI biomarkers [28]. In addition, most patients already
had important elevation of cTn, questioning the validity
of the reported delay from onset of chest pain to pre-
sentation, a factor known to be crucial with regard to
copeptin concentration [19]. Lastly, only a few of these
patients had diabetes, obesity or renal failure, factors
that are associated with increased copeptin concentration
[17,19,29].
The possible role of copeptin in the detection of unstable
angina might be limited, according to Reichlin et al., as they
observed a similar concentration of copeptin in patients with
unstable angina and with non-cardiac cause of chest pain
[19]. However, Keller et al. observed a slight improvement
in the detection of ACS with copeptin in addition to cTn [17].
On the one hand, our results are concordant with the two
studies cited above, as we observed no signiﬁcant difference
in c-statistics with the addition of copeptin to hs-cTnT. On
the other hand, we also observed a slight improvement in
the detection of ACS with the addition of copeptin, which
is similar to the incremental value offered by repetition of
the cTn measurement. This may have clinical implications,
if conﬁrmed in larger series, as it would result in earlier
discharge of patients without ACS.
C
D
D
aious studies [19].
In this study, we examined the ability of our combination
f markers to detect overall ACS. Given the large represen-
ation of unstable angina in our study and other studies,
e assume that considering ACS, rather than AMI solely, is
linically relevant [30,31].
In this study, the ECG was recorded during chest pain in
3% of patients. In addition, echocardiography was recorded
n admission in more than two-thirds of patients and
ngiograms were performed in > 80% of patients; we there-
ore assume that our adjudicated diagnoses were robust.
imitations of our study
ur study is limited by the enrolment of a limited number of
atients and by the inclusion of only one recruiting medical
entre. The results, therefore, are preliminary and need to
e conﬁrmed and extended. In addition, our small sample
ize precluded any subgroup analysis. Although we enrolled
atients admitted to the intensive care unit, we hypothesize
hat our results can be extrapolated to emergency depart-
ents, as long as the use of the assays is limited to patients
resenting with suspected ACS based on a detailed clinical
valuation that includes ECG—a hypothesis to be conﬁrmed
n dedicated studies. As our study was observational, it did
ot measure the possible clinical effects of more accurate
etection of ACS.
onclusions
n conclusion, this prospective study demonstrated that a
ual marker strategy that combined hs-cTnT with copeptin
both measured at admission), increased slightly the detec-
ion of ACS compared with the use of hs-cTnT alone, to a
evel similar to that achieved by repetition of hs-cTnT mea-
urement; the ability of this strategy to enable earlier rule
ut of ACS needs to be assessed by further studies.onﬂict of interest statement
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